April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Validation of the Enhanced Controlled Adverse Environment II
Author Affiliations & Notes
  • George W. Ousler, III
    Ora Institute, Andover, Massachusetts
  • Patrick Johnston
    Ora Institute, Andover, Massachusetts
  • Donna Welch
    Ora Institute, Andover, Massachusetts
  • Keith J. Lane
    Ora Institute, Andover, Massachusetts
  • Mark B. Abelson
    Ora Institute, Andover, Massachusetts
    Schepens Eye Research Institute and Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  George W. Ousler, III, None; Patrick Johnston, None; Donna Welch, None; Keith J. Lane, None; Mark B. Abelson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3857. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      George W. Ousler, III, Patrick Johnston, Donna Welch, Keith J. Lane, Mark B. Abelson; Validation of the Enhanced Controlled Adverse Environment II. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3857.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The Controlled Adverse Environment II (CAE) aims to standardize the study of dry eye in a controlled reproducible environment that challenges the eyes of all patients equally and for the same amount of time. The model exacerbates dry eye signs and symptoms by regulating humidity, temperature, airflow, and lighting conditions. The purpose of the study was to demonstrate the validity, repeatability, and reproducibility of the CAE for assessing ocular discomfort and average corneal staining over inferior, central, and superior regions.

Methods: : Retrospective analysis was based on sign and symptom data from 600 dry eye subjects from the last 4 CAE studies conducted at Ora. Specific endpoints were ocular discomfort (0-4 in unit increments), and average corneal staining over inferior, central, and superior regions (0-4 in half-unit increments). In each study, untreated subjects were exposed to the CAE for 90 minutes at two consecutive visits one week apart. The effect of the chamber was based on pre and post-chamber means at Visits 1 and 2, and the differences between post-chamber means across these visits. These quantities were calculated for each study, and combined differences were calculated as a weighted average of study differences. 95% confidence intervals (CIs) were used to compare post-pre differences between studies.

Results: : Exacerbating effects on means were repeated across visits. For corneal staining, pre and post-chamber means were 1.49 and 2.22 for Visit 1, and 1.49 and 2.25 for Visit 2, giving post-pre differences of 0.73 and 0.76, respectively. For ocular discomfort, pre and post-chamber means were 1.77 and 3.13 for Visit 1, and 2.03 and 3.21 for Visit 2, giving post-pre differences of 1.36 and 1.17, respectively. These post-pre differences were reproducible across studies. For corneal staining, the 95% CI for the difference between visits was (-0.01, 0.08) for the combined sample, and individual study CIs were within ± 0.22. For ocular discomfort, 95% CIs were (0.01, 0.16) for the combined sample, and were within ± 0.29 for all studies.

Conclusions: : CAE validity and repeatability were demonstrated for the combined sample. These attributes were shown to be reproducible across the 4 individual studies.

Keywords: clinical research methodology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.